Rhythm Pharmaceuticals In... (RYTM)
Rhythm Pharmaceuticals Statistics
Share Statistics
Rhythm Pharmaceuticals has 63.22M shares outstanding. The number of shares has increased by 2.19% in one year.
| Shares Outstanding | 63.22M |
| Shares Change (YoY) | 2.19% |
| Shares Change (QoQ) | 0.53% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 56.93M |
| Failed to Deliver (FTD) Shares | 784 |
| FTD / Avg. Volume | 0.15% |
Short Selling Information
The latest short interest is 5.45M, so 8.87% of the outstanding shares have been sold short.
| Short Interest | 5.45M |
| Short % of Shares Out | 8.87% |
| Short % of Float | 9.94% |
| Short Ratio (days to cover) | 9.48 |
Valuation Ratios
The PE ratio is -13.1 and the forward PE ratio is -23.42. Rhythm Pharmaceuticals's PEG ratio is -0.42.
| PE Ratio | -13.1 |
| Forward PE | -23.42 |
| PS Ratio | 26.24 |
| Forward PS | 2.4 |
| PB Ratio | 157.14 |
| P/FCF Ratio | -29.98 |
| PEG Ratio | -0.42 |
Enterprise Valuation
Rhythm Pharmaceuticals Inc. has an Enterprise Value (EV) of 2.59B.
| EV / Earnings | -9.95 |
| EV / Sales | 19.92 |
| EV / EBITDA | -10.89 |
| EV / EBIT | -9.76 |
| EV / FCF | -22.76 |
Financial Position
The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.24 |
| Quick Ratio | 3.08 |
| Debt / Equity | 0.18 |
| Total Debt / Capitalization | 15.34 |
| Cash Flow / Debt | -28.92 |
| Interest Coverage | -12.89 |
Financial Efficiency
Return on equity (ROE) is -11.99% and return on capital (ROIC) is -1035.79%.
| Return on Equity (ROE) | -11.99% |
| Return on Assets (ROA) | -0.66% |
| Return on Capital (ROIC) | -1035.79% |
| Revenue Per Employee | $459,809.19 |
| Profits Per Employee | $-920,855.12 |
| Employee Count | 283 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 0.71 |
Taxes
| Income Tax | 346K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 26.47% in the last 52 weeks. The beta is 2.3, so Rhythm Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 2.3 |
| 52-Week Price Change | 26.47% |
| 50-Day Moving Average | 55.21 |
| 200-Day Moving Average | 52.09 |
| Relative Strength Index (RSI) | 53.63 |
| Average Volume (20 Days) | 514.08K |
Income Statement
In the last 12 months, Rhythm Pharmaceuticals had revenue of 130.13M and earned -260.6M in profits. Earnings per share was -4.21.
| Revenue | 130.13M |
| Gross Profit | 116.76M |
| Operating Income | -265.5M |
| Net Income | -260.6M |
| EBITDA | -238.09M |
| EBIT | -265.5M |
| Earnings Per Share (EPS) | -4.21 |
Balance Sheet
The company has 89.14M in cash and 3.94M in debt, giving a net cash position of 85.2M.
| Cash & Cash Equivalents | 89.14M |
| Total Debt | 3.94M |
| Net Cash | 85.2M |
| Retained Earnings | -1.16B |
| Total Assets | 392.27M |
| Working Capital | 258.68M |
Cash Flow
In the last 12 months, operating cash flow was -113.88M and capital expenditures 0, giving a free cash flow of -113.88M.
| Operating Cash Flow | -113.88M |
| Capital Expenditures | 0 |
| Free Cash Flow | -113.88M |
| FCF Per Share | -1.87 |
Margins
Gross margin is 89.73%, with operating and profit margins of -204.04% and -200.27%.
| Gross Margin | 89.73% |
| Operating Margin | -204.04% |
| Pretax Margin | -200% |
| Profit Margin | -200.27% |
| EBITDA Margin | -182.97% |
| EBIT Margin | -204.04% |
| FCF Margin | -87.51% |
Dividends & Yields
RYTM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -7.68% |
| FCF Yield | -3.29% |
Analyst Forecast
The average price target for RYTM is $70, which is 27.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $70 |
| Price Target Difference | 27.7% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Scores
| Altman Z-Score | 4.06 |
| Piotroski F-Score | 3 |